Inovio Pharmaceuticals (INO) Shares Slide -50% as FDA Review Nears

Key Takeaways

• Inovio Pharmaceuticals (INO) shares have declined roughly 50% over the past 30 days, sliding from a $1.22 close on September 30, 2026, to about $0.61 in late-October trading.
• The selloff centers on the U.S. Food and Drug Administration's review of lead DNA-medicine candidate INO-3107, whose Prescription Drug User Fee Act (PDUFA) target action date fell on October 30, 2026.
• Dilution remains a core concern after a late-July 2026 equity offering raised roughly $18.3 million in net proceeds, alongside a sizable outstanding warrant position.
• Analysts still carry a consensus Buy rating with an average price target near $3.17, although those targets sit far above the current share price.
• A favorable $80.4 million litigation judgment on October 20, 2026, was tempered by uncertainty over the defendants' ability to pay.
• The stock is down more than 50% from its early-September peak near $1.45, underscoring the volatility tied to the regulatory catalyst.
• For additional detail, explore this ticker's Price Targets, Earnings, and Forecast pages.
• Investors tracking momentum can also explore Trending AI Robots.

Inovio Pharmaceuticals (INO) Company Overview and Market Position

Inovio Pharmaceuticals is a clinical-stage biotechnology company focused on DNA medicines designed to treat and protect people from HPV-related diseases, cancer, and infectious diseases. Its platform combines SynCon, a process for engineering precisely designed plasmid DNA, with proprietary CELLECTRA delivery devices that administer the plasmids without chemical adjuvants, lipid nanoparticles, or viral vectors. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The company's lead candidate, INO-3107, is being developed for recurrent respiratory papillomatosis (RRP), a rare, chronic disease driven by HPV types 6 and 11. The broader pipeline includes VGX-3100 for HPV-related cervical high-grade lesions, INO-3112 for HPV-related oropharyngeal squamous cell carcinoma, and INO-5401 for glioblastoma. Investors follow INO primarily for the regulatory and commercialization milestones tied to INO-3107.

Inovio Pharmaceuticals (INO) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, INO has fallen roughly 50%. Shares closed at $1.22 on September 30, 2026, and traded near $0.61 in late October, with the steepest losses concentrated in the final two weeks of the period. The move accelerated sharply on October 21 and again on October 29 and 30, when unusually heavy volume accompanied the decline.

The trailing three-month picture is more complex. After a late-July equity offering sent shares sharply lower, the stock staged a powerful recovery, climbing from below $0.70 in early August to roughly $1.45 by early September. That rally then reversed, and the stock gave back its gains through October. As a result, INO sits well below its quarterly peak even though its net change versus the end of July is comparatively modest.

What Drove INO Stock Price in the Last 30 Days

The dominant driver was the FDA's review of INO-3107. The company's Biologics License Application (BLA) was filed under the accelerated approval pathway, and the PDUFA target action date fell on October 30, 2026. As that date approached, investor caution increased, and the stock sold off sharply around the decision window amid uncertainty over the approval outcome. From what I see, this regulatory overhang explains much of the recent pressure.

Secondary factors compounded the pressure. A 91-day lock-up agreement tied to the July 2026 offering expired on October 28, 2026, potentially freeing additional shares for sale. Persistent dilution concerns, including a substantial outstanding warrant position and a limited cash runway, weighed on sentiment. On October 20, Inovio announced an $80.4 million favorable judgment in its litigation against VGXI and GeneOne Life Science, but the company cautioned that the defendants' financial condition could impair collection, limiting the news's positive impact. Piper Sandler reiterated a Buy rating and a $4.00 price target on October 21, yet the analyst support was not enough to offset the regulatory-driven selling.

What Drove INO Stock Performance Over the Last Quarter

The quarter's defining theme was volatility around INO-3107 and the company's balance sheet. In late July, Inovio completed an equity offering that generated about $18.3 million in net proceeds, extending its cash runway into late first-quarter 2027 but triggering a steep one-day decline as investors absorbed the dilution.

Shares then recovered strongly into early September, lifted by optimism ahead of the FDA decision and by upbeat pipeline updates, including positive Phase 3 results announced by its Greater China partner for VGX-3100. That momentum faded as the PDUFA date neared, and the lock-up expiration added a fresh overhang in late October. The net result is a stock that has largely round-tripped over the period and now trades below the levels seen for much of the summer. I’m watching this closely for any signs of stabilization post-decision.

INO Stock Forecast Drivers: What Investors Should Watch Next

Investors should monitor the regulatory outcome for INO-3107 and any company disclosures on next steps, including potential confirmatory-trial requirements or resubmission plans. Near-term financial health is another key factor: management has guided to a cash runway into late first-quarter 2027, making capital-raising activity, warrant exercise, and cash burn important data points. Commercial launch preparations, manufacturing readiness, and any updates on VGX-3100's regulatory progress in Greater China also matter for the broader pipeline story. Finally, analyst revisions and institutional positioning could influence sentiment as the market digests the FDA's decision.

Exploring Tickeron’s AI Trend Prediction Engine

One tool I find particularly useful for these situations is Tickeron’s AI Trend Prediction Engine. It helps surface pattern-based signals across thousands of tickers, allowing me to cross-check momentum and volatility trends without relying solely on manual review. I often use it alongside other data points when evaluating biotech names like this one.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume